S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead

Akero Therapeutics (AKRO) Stock Price, News & Analysis

$21.72
-0.46 (-2.07%)
(As of 04/15/2024 ET)
Today's Range
$21.49
$22.40
50-Day Range
$17.76
$31.18
52-Week Range
$11.25
$58.38
Volume
757,560 shs
Average Volume
1.30 million shs
Market Capitalization
$1.22 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$39.00

Akero Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
79.6% Upside
$39.00 Price Target
Short Interest
Healthy
13.93% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.75
Upright™ Environmental Score
News Sentiment
1.60mentions of Akero Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$3.32 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($4.06) to ($4.49) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.75 out of 5 stars

Medical Sector

232nd out of 928 stocks

Pharmaceutical Preparations Industry

95th out of 428 stocks

AKRO stock logo

About Akero Therapeutics Stock (NASDAQ:AKRO)

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

AKRO Stock Price History

AKRO Stock News Headlines

REVEALED: Elon Musk’s Secret A.I. Facility?
I recently shot this video outside what could be Elon Musk’s biggest secret. What’s happening inside these walls is so important that our government has declared it a matter of national security.
Akero Therapeutics' EFX Data Warrants Caution
REVEALED: Elon Musk’s Secret A.I. Facility?
I recently shot this video outside what could be Elon Musk’s biggest secret. What’s happening inside these walls is so important that our government has declared it a matter of national security.
AKRO Apr 2024 42.500 call
AKRO Aug 2024 30.000 put
AKRO Aug 2024 17.500 put
AKRO Jan 2025 2.500 call
Akero Therapeutics Commences Public Offering Of $300 Mln Of Shares
See More Headlines
Receive AKRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akero Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/29/2024
Today
4/15/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AKRO
Fax
N/A
Employees
55
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$39.00
High Stock Price Target
$43.00
Low Stock Price Target
$33.00
Potential Upside/Downside
+79.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-151,760,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$9.61 per share

Miscellaneous

Free Float
50,843,000
Market Cap
$1.22 billion
Optionable
Optionable
Beta
-0.38
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Andrew Cheng M.D. (Age 57)
    Ph.D., President, CEO & Director
    Comp: $1.22M
  • Dr. Jonathan M. Young J.D. (Age 54)
    Ph.D., Co-Founder, Executive VP, COO & Secretary
    Comp: $763.3k
  • Dr. Timothy Rolph (Age 70)
    Co-Founder & Chief Scientific Officer
    Comp: $819.4k
  • Mr. William R. White J.D. (Age 50)
    Executive VP, CFO, Treasurer & Head of Corporate Development
    Comp: $768.4k
  • Ms. Catriona YaleMs. Catriona Yale (Age 52)
    Executive VP & Chief Development Officer
    Comp: $754.8k
  • Mr. Patrick Lamy (Age 51)
    Senior Vice President of Commercial Strategy
  • Mr. John J. Schembri (Age 62)
    VP of Finance & Controller

AKRO Stock Analysis - Frequently Asked Questions

Should I buy or sell Akero Therapeutics stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Akero Therapeutics in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AKRO shares.
View AKRO analyst ratings
or view top-rated stocks.

What is Akero Therapeutics' stock price target for 2024?

6 Wall Street research analysts have issued 1-year price targets for Akero Therapeutics' shares. Their AKRO share price targets range from $33.00 to $43.00. On average, they anticipate the company's stock price to reach $39.00 in the next year. This suggests a possible upside of 79.6% from the stock's current price.
View analysts price targets for AKRO
or view top-rated stocks among Wall Street analysts.

How have AKRO shares performed in 2024?

Akero Therapeutics' stock was trading at $23.35 at the beginning of 2024. Since then, AKRO stock has decreased by 7.0% and is now trading at $21.72.
View the best growth stocks for 2024 here
.

Are investors shorting Akero Therapeutics?

Akero Therapeutics saw a drop in short interest in March. As of March 31st, there was short interest totaling 7,840,000 shares, a drop of 17.2% from the March 15th total of 9,470,000 shares. Based on an average trading volume of 1,360,000 shares, the short-interest ratio is currently 5.8 days.
View Akero Therapeutics' Short Interest
.

When is Akero Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our AKRO earnings forecast
.

How were Akero Therapeutics' earnings last quarter?

Akero Therapeutics, Inc. (NASDAQ:AKRO) issued its quarterly earnings results on Thursday, February, 29th. The company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.82) by $0.17.

What ETFs hold Akero Therapeutics' stock?

ETFs with the largest weight of Akero Therapeutics (NASDAQ:AKRO) stock in their portfolio include Simplify Propel Opportunities ETF (SURI), Invesco Dorsey Wright SmallCap Momentum ETF (DWAS) and ALPS Medical Breakthroughs ETF (SBIO).Simplify Health Care ETF (PINK).

What other stocks do shareholders of Akero Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akero Therapeutics investors own include Fulcrum Therapeutics (FULC), Kaleido Biosciences (KLDO), Sorrento Therapeutics (SRNE), Editas Medicine (EDIT), Gossamer Bio (GOSS), Provention Bio (PRVB), Alector (ALEC), Micron Technology (MU), VIVUS (VVUS).

When did Akero Therapeutics IPO?

Akero Therapeutics (AKRO) raised $75 million in an initial public offering (IPO) on Thursday, June 20th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Jefferies and Evercore ISI acted as the underwriters for the IPO and Roth Capital Partners was co-manager.

Who are Akero Therapeutics' major shareholders?

Akero Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.01%). Insiders that own company stock include Andrew Cheng, Catriona Yale, G Walmsley Graham, Jonathan Young, Kevin Bitterman, Seth Loring Harrison, Skorpios Trust, Timothy Rolph, Tomas J Heyman and William Richard White.
View institutional ownership trends
.

How do I buy shares of Akero Therapeutics?

Shares of AKRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AKRO) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners